We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Personal Continuous Glucose Monitoring Device Validated

By LabMedica International staff writers
Posted on 17 Sep 2008
A personal continuous glucose-monitoring (CGM) device significantly reduced the average blood glucose levels (A1c) of adult patients with type 1 diabetes. More...
This further validated the ability of the device to substantially improve diabetes management and glucose control. Reducing A1c can result in reduced risk of long-term side effects associated with diabetes, including blindness and kidney disease.

A multicenter, 322-patient trial, funded by the Juvenile Diabetes Research Foundation (JDRF; New York, NY, USA), found that after six months adults using the personal CGM realized a statistically significant 0.53% absolute reduction in A1c as compared to the control group. All patients in the study experienced statistically significant absolute reductions in A1c levels ranging from 0.5-0.7% when the personal CGM was used at least six days a week. Moreover, improvements in A1c occurred without an increase in severe hypoglycemia (low blood sugar).

Medtronic (Northridge, CA, USA) currently markets the integrated diabetes management system that combines the personal CGM with insulin pump therapy. It is called the MiniMed Paradigm Real-Time system. Medtronic also offers a stand-alone personal CGM device--the Guardian Real-Time system.

Medtronic is a world leader in advanced diabetes management solutions. Their products include integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems, and therapy management software.

"We are confident that the JDRF study results will aid physicians' efforts to bring personal CGM to more patients,” said Chris O'Connell, president of the diabetes business at Medtronic. "In fact, healthcare insurers are already seeing value in this technology. Many have policies for personal CGM devices, and new coverage decisions are being made regularly.”

Results from the multicenter study were presented on September 8, 2008, during the European Association for the Study of Diabetes annual meeting in Rome, Italy, and portions of the data will be published in the October 2, 2008, issue of the New England Journal of Medicine, which is also available online.

Related Links:
Juvenile Diabetes Research Foundation
Medtronics


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.